MarketPulse

asthma

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Kymera Therapeutics Lands $45M Milestone as FDA Fast-Tracks Asthma Drug

Kymera Therapeutics receives $45M from Gilead option exercise and FDA Fast Track designation for asthma drug KT-621, with Phase 2b data expected late 2027.
GILDKYMRasthmaGilead Sciences
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Respiratory Care Device Market to Double to $47.5B by 2034 on Disease Surge

Global respiratory care devices market projected to grow 8% annually to $47.5B by 2034, driven by chronic disease prevalence and home healthcare demand.
MDTRMDPHGGEHCmarket growthCOPD
BenzingaBenzinga··Vandana Singh

Sanofi's Dual-Action Drug Shows Promise Beyond Lungs in Asthma, Polyp Trials

Sanofi's lunsekimig met primary endpoints in asthma and nasal polyp trials but failed dermatitis goals, showing favorable safety across all studies.
SNYUPBREGNGSKatopic dermatitisPhase 2 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Lunsekimig Clears Key Phase 2 Hurdles in Asthma and Sinus Disease

Sanofi's bispecific antibody lunsekimig met primary endpoints in phase 2 asthma and chronic rhinosinusitis studies, though atopic dermatitis trial missed targets.
SNYchronic rhinosinusitis with nasal polypsatopic dermatitis
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Lunsekimig Clears Key Phase 2 Goals in Asthma, Nasal Polyps

Sanofi's lunsekimig met primary endpoints in Phase 2 asthma and nasal polyps trials but failed in atopic dermatitis, advancing respiratory programs with favorable safety.
SNYatopic dermatitisimmunology
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aclaris Advances Dual-Target Antibody into Asthma Study Following Dermatitis Trial Launch

Aclaris launches Phase 1b asthma trial for ATI-052, a dual-target antibody also in dermatitis trials. Results expected mid-2026.
ACRSclinical developmentatopic dermatitis